{
    "clinical_study": {
        "@rank": "16690", 
        "arm_group": {
            "arm_group_label": "Live Attenuated Varicella Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to observe the persistence of protection, duration of\n      protection, safety and breakthrough infection rates afforded by live attenuated varicella\n      vaccine in children over a 5-year period."
        }, 
        "brief_title": "Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Chickenpox", 
        "condition_browse": {
            "mesh_term": "Chickenpox"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant are healthy children aged 1-6 years, who has inquired for         medical\n             history and physical examination, and met the requirement of the vaccine trial\n\n          -  Parent/legal acceptable representative is willing and able to understand the protocol\n             requirements and provide informed consent\n\n          -  Subject and parent/guardian able to attend all scheduled visits and comply with all\n             trial procedures\n\n          -  Body temperature \u226437\u2103\n\n        Exclusion Criteria:\n\n          -  Participant with previous history of chickenpox or zoster\n\n          -  Receipt of varicella vaccine\n\n          -  Reported the family history of allergies, convulsions, epilepsy and mental illness\n\n          -  Known allergy to any constituent of the vaccine\n\n          -  Known serve illness, in a fever, acute infection and chronic disease activity\n\n          -  Receipt of steroid\n\n          -  Reported the history of thrombocytopenia or other coagulation disorders, which may\n             cause\n\n          -  Known or suspected impairment of immunologic function, or receipt of\n             immunosuppressive therapy or immunoglobulin since birth\n\n          -  Known congenital malformation, developmental disorders and severe chronic disease\n             (e.g. Down's syndrome, diabetes, sickle cell anemia and neurologic disorders)\n\n          -  Known dermatopathy with allergy, herpes, fester, and fungal infection\n\n          -  Receipt of whole blood, blood plasma or immunoglobulin in the 3 months preceding the\n             trial vaccination\n\n          -  Reported the history of acute illness had need systemic antibiotics or anti-viral\n             treatment of infections in the 7 days preceding the trial vaccination\n\n          -  Participant with fever(temperature\u2265 38\u2103) in the days\n\n          -  Any condition, which, in the opinion of the investigator, would pose a health risk to\n             the subject"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982409", 
            "org_study_id": "NCT02038508"
        }, 
        "intervention": {
            "arm_group_label": "Live Attenuated Varicella Vaccine", 
            "intervention_name": "Live Attenuated Varicella Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Maoming", 
                    "country": "China", 
                    "state": "Guangdong"
                }, 
                "name": "Maoming Center for Disease Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study of Immune Persistence After Inoculated With One-dose Freeze-dried Live Attenuated Varicella Vaccine in Children Aged 1-6 Years", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical subjects are drawn 3ml's vein blood\uff0crespectively before vaccination, six weeks and every year in 5 years study period after inoculation of the live varicella vaccine. FAMA methods are used to test antibody rate of pox virus.", 
            "measure": "Immune protective effect and persistence after inoculated with live attenuated varicella vaccine", 
            "safety_issue": "No", 
            "time_frame": "Before vaccination, six weeks and every year in 5 years study period after inoculation of the live varicella vaccine"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982409"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Breakthrough rate, duration and severity of varicella in vaccinated children", 
                "safety_issue": "No", 
                "time_frame": "5 years period"
            }, 
            {
                "measure": "Occurrence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks after vaccination"
            }
        ], 
        "source": "Changchun Changsheng Life Science and Technology Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Guangdong Provincial Institute of Biological Products And Materia Medica", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Changchun Changsheng Life Science and Technology Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}